The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology

Abstract Canada has among the highest incidence and prevalence of inflammatory bowel disease (IBD) in the world. After decades of rising incidence of IBD in Canada during the 20th Century, the prevalence of IBD in 2018 is 0.7% of the Canadian population. Forecasting models predict that prevalence of IBD will continue to rise to 1.0% of the population by 2030. In 2018, the number of Canadians living with IBD is approximately 270,000 and is predicted to rise to 403,000 Canadians in 2030. Inflammatory bowel disease affects all age groups with adolescents and young adults at highest risk of diagnosis. Canadians of all ethnicities are being diagnosed with IBD including known high-risk groups such as Ashkenazi Jews and offspring of South Asian immigrants who were previously thought to be low risk. Moreover, IBD has evolved into a global disease with rising incidence in newly industrialized countries in Asia and South America. The causes of IBD remain unsolved; however, the high rates of disease in Western countries and its emergence in newly industrialized countries suggest that environmental factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. Highlights 1. Canada continues to have among the highest prevalence of IBD in the world. 2. Today, approximately 270,000 Canadians live with IBD. By 2030 it is estimated that nearly 403,000 Canadians will have a diagnosis of IBD. 3. Inflammatory bowel disease has become a worldwide disease with increasing rates in Asia, Africa, and South America—continents where IBD was rarely diagnosed prior to 1990. 4. The causes of IBD are unknown, but the high rates of disease over the past 60 years in Western countries and the emergence of disease in developing countries suggest that factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. 5. Many of the leading hypotheses as to the causes of IBD tie in with alteration of the gut microbiome, the suite of organisms that reside in the bowel and maintain bowel health throughout life. Key Summary Points 1. The incidence (the number of new diagnoses annually) of IBD rose throughout the 20th century in Canada and then stabilized at the turn of the 21st century. 2. The prevalence (the total number of diagnosed persons in the population) of IBD in Canada is among the highest in the world. 3. Today, 270,000 (0.7%, or 7 in 1000) Canadians are estimated to live with IBD. By 2030, that number is expected to rise to 403,000 Canadians (1% or 1 in 100). 4. Inflammatory bowel disease can be diagnosed at any age. However, the age groups that are most likely to be diagnosed are adolescents and young adults from 20 to 30 years of age. 5. Inflammatory bowel disease in Canada affects the lives of Canadians of all ethnicities, including known high-risk groups such as Ashkenazi Jews, and those thought previously to be at low risk, such as first-generation offspring of South Asian immigrants. 6. Canadian health policy makers will need to prepare the Canadian health care system for the rising burden of IBD. 7. As newly industrialized countries in Asia, Africa, and South America are transitioning to a Westernized society, IBD has emerged and its incidence in these countries is rising rapidly. 8. The gut microbiome includes microorganisms that maintain digestive health. Thus, changes in the microbiome, which may change the immune system’s response to triggers, may be important in initiating and perpetuating IBD. 9. A number of factors can alter the gut microbiome and early childhood may be a particularly important time such that breastfeeding, early life diet, use of antibiotics, infections, and other environmental exposures may impact the gut microbiome in such a way that facilitates developing IBD. 10. Smoking is associated with an increased risk and worsening disease course of Crohn’s disease. Quitting smoking is associated with an increased risk of developing ulcerative colitis. Therefore, never initiating smoking can mitigate the risk for IBD. Educational programs aimed at those at-risk for IBD should emphasize the risk of starting to smoke tobacco. 11. Modifying exposure to environmental risk factors associated with the Westernization of society (e.g., Western diet and lifestyles) may provide an avenue for reducing the risk of IBD in Canada and worldwide. Gaps in Knowledge and Future Directions 1. While the incidence of IBD appears to be stabilizing in some regions in Canada, IBD may be occurring more frequently in certain populations such as in children, South Asians, Ashkenazi Jews, and immigrants. Future research should focus on the changing demographics of IBD in Canada. 2. The prevalence of IBD will rise steadily over the next decade. To enable better health care system planning and to respond adequately to the increasing burden of IBD, ongoing surveillance of the epidemiology and health services utilization of IBD in Canada is necessary. 3. Most studies have focused on the mortality associated with IBD. Future research is necessary to assess health-adjusted life expectancy and overall life expectancy for those living with IBD. 4. Analyses of resources, infrastructure, and personnel need to be modeled into the future in order to prepare our health care system for the rising burden of IBD. 5. Research on the interaction between genes, microbes, and our environment will inform our understanding of the pathogenesis of IBD, information necessary to prevent IBD in the future.

[1]  G. Kaplan,et al.  A29 THE RISING PREVALENCE OF INFLAMMATORY BOWEL DISEASE IN CANADA: ANALYZING THE PAST TO PREDICT THE FUTURE , 2018 .

[2]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[3]  Y. Naito,et al.  Gut microbiota in the pathogenesis of inflammatory bowel disease , 2018, Clinical Journal of Gastroenterology.

[4]  C. Bernstein,et al.  Review article: changes in the epidemiology of inflammatory bowel disease—clues for aetiology , 2017, Alimentary pharmacology & therapeutics.

[5]  D. Iliopoulos,et al.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy , 2017, Nature Reviews Gastroenterology & Hepatology.

[6]  E. Rahme,et al.  Cost of Ulcerative Colitis in Quebec, Canada: A Retrospective Cohort Study , 2017, Inflammatory bowel diseases.

[7]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[8]  D. Tanyingoh,et al.  Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases , 2017, The American Journal of Gastroenterology.

[9]  C. Bernstein,et al.  Risk of Surgery and Mortality in Elderly-onset Inflammatory Bowel Disease: A Population-based Cohort Study , 2017, Inflammatory bowel diseases.

[10]  S. Ng,et al.  Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. , 2017, Gastroenterology.

[11]  S. Ng,et al.  Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. , 2016, The lancet. Gastroenterology & hepatology.

[12]  Judy H. Cho,et al.  A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. , 2016, Gastroenterology.

[13]  T. Vatanen,et al.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease , 2016, Genome Medicine.

[14]  G. Kaplan,et al.  The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis , 2016, Clinical and Translational Gastroenterology.

[15]  A. Bitton,et al.  Mortality Trends in Crohn's Disease and Ulcerative Colitis: A Population-based Study in Québec, Canada , 2016, Inflammatory bowel diseases.

[16]  B. Bressler,et al.  Pediatric Inflammatory Bowel Disease Among South Asians Living in British Columbia, Canada: A Distinct Clinical Phenotype , 2016, Inflammatory Bowel Diseases.

[17]  G. Kaplan,et al.  The global burden of IBD: from 2015 to 2025 , 2015, Nature Reviews Gastroenterology &Hepatology.

[18]  K. Meng,et al.  New Insights into the Role of T3 Loop in Determining Catalytic Efficiency of GH28 Endo-Polygalacturonases , 2015, PloS one.

[19]  T. To,et al.  Asthma, Type 1 and Type 2 Diabetes Mellitus, and Inflammatory Bowel Disease amongst South Asian Immigrants to Canada and Their Children: A Population-Based Cohort Study , 2015, PloS one.

[20]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[21]  T. To,et al.  Inflammatory Bowel Disease in Immigrants to Canada And Their Children: A Population-Based Cohort Study , 2015, The American Journal of Gastroenterology.

[22]  P. Kawalec,et al.  Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis , 2015, Expert review of pharmacoeconomics & outcomes research.

[23]  A. Ananthakrishnan Environmental Risk Factors for Inflammatory Bowel Diseases: A Review , 2015, Digestive Diseases and Sciences.

[24]  L. Lix,et al.  Predictors and risks for death in a population-based study of persons with IBD in Manitoba , 2014, Gut.

[25]  C. Bernstein,et al.  Antibiotics Associated With Increased Risk of New-Onset Crohn’s Disease But Not Ulcerative Colitis: A Meta-Analysis , 2014, The American Journal of Gastroenterology.

[26]  J. Cheon,et al.  Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. , 2014, World journal of gastroenterology.

[27]  N. Pedersen,et al.  Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study. , 2014, Journal of Crohn's & colitis.

[28]  W. Willett,et al.  A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. , 2013, Gastroenterology.

[29]  S. Ng,et al.  Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. , 2013, Gastroenterology.

[30]  P. Lakatos,et al.  The burden of inflammatory bowel disease in Europe. , 2013, Journal of Crohn's & colitis.

[31]  G. Kaplan,et al.  Environmental Particulate Matter Induces Murine Intestinal Inflammatory Responses and Alters the Gut Microbiome , 2013, PloS one.

[32]  G. Kaplan,et al.  Environment and the inflammatory bowel diseases. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[33]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[34]  Michael D. Kappelman,et al.  Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population , 2012, Digestive Diseases and Sciences.

[35]  C. Bernstein,et al.  Direct Medical Cost of Managing IBD Patients: A Canadian Population‐based Study , 2012, Inflammatory bowel diseases.

[36]  A. Ananthakrishnan,et al.  Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis , 2012, Annals of Internal Medicine.

[37]  E. Giovannucci,et al.  Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. , 2012, Gastroenterology.

[38]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[39]  G. Kaplan Air pollution and the inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[40]  A. Griffiths,et al.  Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends , 2011, Inflammatory bowel diseases.

[41]  F. Clavel-Chapelon,et al.  Animal Protein Intake and Risk of Inflammatory Bowel Disease: The E3N Prospective Study , 2010, The American Journal of Gastroenterology.

[42]  K. Gradel,et al.  Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. , 2009, Gastroenterology.

[43]  E. Riboli,et al.  Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case–control study within a European prospective cohort study , 2009, Gut.

[44]  H. R. Nunes,et al.  Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. , 2009, Arquivos de gastroenterologia.

[45]  C. Yurdaydın,et al.  Clinical Characteristics of Inflammatory Bowel Disease in Turkey: A Multicenter Epidemiologic Survey , 2009, Journal of clinical gastroenterology.

[46]  A. Zhernakova,et al.  Detecting shared pathogenesis from the shared genetics of immune-related diseases , 2009, Nature Reviews Genetics.

[47]  R. Goetzel,et al.  The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative Colitis , 2008, Journal of occupational and environmental medicine.

[48]  D. Tribble,et al.  Infectious gastroenteritis and risk of developing inflammatory bowel disease. , 2008, Gastroenterology.

[49]  J. Halfvarson,et al.  Environmental factors in inflammatory bowel disease: A co‐twin control study of a Swedish‐Danish twin population , 2006, Inflammatory bowel diseases.

[50]  C. Bernstein,et al.  A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. , 2006, American journal of epidemiology.

[51]  Mieke Koehoorn,et al.  The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study , 2006, The American Journal of Gastroenterology.

[52]  J. Panés,et al.  Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. , 2006, Gastroenterology.

[53]  M. Cheang,et al.  A Population-Based Case Control Study of Potential Risk Factors for IBD , 2006, The American Journal of Gastroenterology.

[54]  J. Leighton,et al.  Relapse of Inflammatory Bowel Disease Associated With Use of Nonsteroidal Anti-Inflammatory Drugs , 2006, Digestive Diseases and Sciences.

[55]  K. Wakai,et al.  Dietary Risk Factors for Inflammatory Bowel Disease: A Multicenter Case‐Control Study in Japan , 2005, Inflammatory bowel diseases.

[56]  Beverly M. Calkins DHSc A meta-analysis of the role of smoking in inflammatory bowel disease , 2005, Digestive Diseases and Sciences.

[57]  E. Loftus Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[58]  A. Sood,et al.  Incidence and prevalence of ulcerative colitis in Punjab, North India , 2003, Gut.

[59]  C. Bernstein,et al.  Work Losses Related to Inflammatory Bowel Disease in Canada: Results From a National Population Health Survey , 2003, American Journal of Gastroenterology.

[60]  M. Gleeson,et al.  Non‐steroidal anti‐inflammatory drugs, aspirin and newly diagnosed colitis: a case–control study , 2003, Alimentary pharmacology & therapeutics.

[61]  A. Ekbom,et al.  Appendectomy and protection against ulcerative colitis. , 2001, The New England journal of medicine.

[62]  S. Fisher,et al.  Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations , 2001, The Lancet.

[63]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[64]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[65]  B. Korelitz,et al.  Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study , 2000, American Journal of Gastroenterology.

[66]  P. Dagnelie,et al.  Diet as a risk factor for the development of ulcerative colitis , 2000, American Journal of Gastroenterology.

[67]  J. Mayberry,et al.  The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second-generation South Asians in Leicester (1991–1994) , 1999, American Journal of Gastroenterology.

[68]  S. Reif,et al.  Pre-illness dietary factors in inflammatory bowel disease. , 1997, Gut.

[69]  J. Evans,et al.  Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. , 1997, Gut.

[70]  T. Vaughan,et al.  Increased risk of inflammatory bowel disease associated with oral contraceptive use. , 1994, American journal of epidemiology.

[71]  C. Probert,et al.  Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. , 1992, Gut.

[72]  D. P. Strachan,et al.  Hay fever, hygiene, and household size. , 1989, BMJ.

[73]  J. Rotter,et al.  Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. , 1989, Gastroenterology.